 | Up a level |
Engert, A., Fanale, M., Santoro, A., Armand, P., Ansell, S., Zinzani, P. L., Timmerman, J., Collins, G., Ramchandren, R., Cohen, J., De Boer, J. P., Kuruvilla, J., Savage, K., Trneny, M., Rodig, S., Shipp, M., Kato, K., Sumbul, A., Farsaci, B. and Younes, A. (2017). NIVOLUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER AUTOLOGOUS TRANSPLANT: FULL RESULTS AFTER EXTENDED FOLLOW-UP OF THE MULTICOHORT MULTICENTER PHASE 2 CHECKMATE 205 TRIAL. Haematologica, 102. S. 145 - 146. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Engert, A., Santoro, A., Shipp, M., Zinzani, P. L., Timmerman, J., Ansell, S., Armand, P., Fanale, M., Ratanatharathorn, V., Kuruvilla, J., Cohen, J., Collins, G., Savage, K., Trneny, M., Kato, K., Farsaci, B., Parker, S., Rodig, S. and Younes, A. (2016). CHECKMATE 205: A PHASE 2 STUDY OF NIVOLUMAB IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION AND BRENTUXIMAB VEDOTIN. Haematologica, 101. S. 319 - 320. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Jaeger, U., Engert, A., Fanale, M., Santoro, A., Armand, P., Ansell, S., Zinzani, P. L., Timmerman, J. M., Collins, G. P., Ramchandren, R., Cohen, J. B., De Boer, J. P., Kuruvilla, J., Savage, K. J., Trneny, M., Rodig, S., Shipp, M., Kato, K., Sumbul, A., Farsaci, B. and Younes, A. (2017). Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: full results after extended follow-up of the multicohort, multicenter phase 2 CheckMate 205 trial. Oncol. Res. Treat., 40. S. 13 - 15. BASEL: KARGER. ISSN 2296-5262
Lena, H., Rizvi, N. A., Wolf, J., Cappuzzo, F., Zalcman, G., Baas, P., Mazieres, J., Farsaci, B., Blackwood-Chirchir, M. A. and Ramalingam, S. (2016). Nivolumab in patients (pts) with advanced refractory squamous (SQ) non-small cell lung cancer (NSCLC): 2-year follow-up from CheckMate 063 and exploratory cytokine profiling analyses. J. Thorac. Oncol., 11 (4). S. S115 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380